Sellers must label unapproved peptides for research use only, but that warning may soon be dropped. Users describe bad reactions they blame on them.
Recap by typeshit. Full story at CNN on MSN.
Reuters reports the trend among GLP-1 users is prompting calls for tighter rules on supplements sold alongside the drugs.
A pharmacist account flags two separate Class II recalls involving compounded tirzepatide. Tap through for which products are affected and why.
Health authorities in New South Wales issued a warning after a jump in hospitalisations linked to unapproved peptides sold as wellness products.
A University of Iowa chemist found no peptide in a Brooklyn corner-store vial, and another expert flagged at least 13 bacterial colonies that could cause infection.
Across nearly 44,000 matched patients over 65, GLP-1 users had a 45% lower death risk, researchers report, though they also saw more osteoporosis and retinopathy.
Their accounts come as sellers of unapproved 'research use only' peptides may soon be allowed to stop printing that warning on their products.
Loading…